Clinical trial · Interventional
Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy
PANasta Trial Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy - a Double Blinded Multi Centred Trial
NCT02457156CI-TRIAL-00087160PANastacompletedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to compare two different techniques of performing a pancreatic anastomosis; Cattell-Warren versus Blumgart to determine if a Blumgart anastomosis reduces pancreatic remnant leak, post-operative complications and overall length of hospital stay.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blumgart Anastomosis | Procedure | — | UNRESOLVED |
| Cattell-Warren Anastomosis | Procedure | — | UNRESOLVED |
| Octreotide | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Blumgart Anastomosis
- description
- Re-construction of the pancreatic remnant following pancreatico-duodenectomy using a "Blumgart" method of pancreatico-jejunostomy. Octreotide will be administered.
- interventionNames
- Procedure: Blumgart Anastomosis
- Drug: Octreotide
- type
- ACTIVE_COMPARATOR
- label
- Cattell-Warren Anastomosis
- description
- Re-construction of the pancreatic remnant following pancreato-duodenectomy using a "Cattell-Warren" method of pancreatico-jejunostomy. Octreotide will be administered.
- interventionNames
- Procedure: Cattell-Warren Anastomosis
- Drug: Octreotide
Primary outcomes (1)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients undergoing an elective pancreato-duodenectomy for presumed malignancy. * Ability of the subject to understand the nature and consequences of the trial. * Ability to rovide writen informed consent. * Age 18 or greater. Exclusion Criteria: * Patients undergoing extended pancreato-duodenectomy * Left, central or total pancreatectomy. * Arterial resection or multi-visceral resection * Previous pancreatic surgery * Surgery for known chronic pancreatitis. * Recruited to any other pancreatic resection trial. * Pregnant women. * Women of childbearing potential, including women whose last menstrual period was less than one year prior to screening, unable or unwilling to use adequate contraception from time of consent up to the day of surgery.
References
Publications (0)
Data not yet available
No reference posted for this study.